Modern melanoma treatment in the UK
26 Oct 2018
Modern melanoma treatment in the UK
Current clinical landscape for ALK non-small cell lung cancer patients
Latest advances in treatment for ALK positive NSCLC
The case for biosimilars
Highlights in early non-metastatic NSCLC and thoracic tumours
Highlights in SCLC from ESMO 2018
Safety analysis of entrectinib for NTRK fusion tumours
CheckMate142: Checkpoint combination therapy in first-line colorectal cancer
SOLO1: Maintenance olaparib in advanced BRCA ovarian cancer
Lung highlights from ESMO 2018
Erlotinib for neoadjuvant treatment of EGFR NSCLC
AURA 3: Mechanisms of osimertinib resistance in patients with EGFR T790M advanced NSCLC